Comparative study of weekly and three-weekly neoadjuvant carboplatin in triple-negative breast cancer: retrospective analysis in real-world settings
ConclusionsWeekly carboplatin exhibited comparable toxicity, a trend toward fewer interruptions, and similar pCR rates. Prospective studies are essential for validating these findings.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Breast Conservation Surgery | Cancer | Cancer & Oncology | Hematology | Neoadjuvant Therapy | Study | Toxicology